|
|
|
|
The first primary outcome - a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke - occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (r elative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001). The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation. However , the risk of major bleeding is increased among patients treated with clopidogrel. |
|